Education
About Us
Working with TipRanks
Follow Us
Applied DNA Sciences (APDN)
NASDAQ:APDN
Top Page
Applied DNA Sciences
(NASDAQ:APDN)
Rating:42Neutral
Price Target:―
Applied DNA Sciences (APDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.49M
Dividend YieldN/A
Average Volume (3M)113.25K
Price to Earnings (P/E)―
Beta (1Y)2.52
Revenue Growth-2.96%
EPS Growth89.71%
CountryUS
Employees46
SectorHealthcare
Sector Strength47
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-33.41
Shares Outstanding1,291,465
10 Day Avg. Volume61,491
30 Day Avg. Volume113,248
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.38
Enterprise Value/Revenue-0.52
Enterprise Value/Gross Profit-1.32
Enterprise Value/Ebitda0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Applied DNA Sciences Business Overview & Revenue Model
Company DescriptionApplied DNA Sciences (APDN) is a biotechnology company specializing in DNA-based solutions. The company operates in sectors such as pharmaceuticals, textiles, and security. Its core products and services include DNA tagging, DNA-based authentication, and security solutions that help verify the originality and authenticity of products and materials.
How the Company Makes MoneyApplied DNA Sciences generates revenue through the sale of its proprietary DNA-based solutions and services. The company earns money by providing DNA tagging and authentication services to businesses in various industries, including pharmaceuticals, textiles, and consumer goods. Additionally, APDN collaborates with partners in sectors like government and law enforcement to deliver security solutions. Key revenue streams include service fees for DNA tagging and authentication, as well as licensing fees from strategic partnerships. APDN's earnings are significantly influenced by its ability to secure contracts with major companies and government agencies, as well as its continued innovation in DNA technology applications.
Applied DNA Sciences Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q1-2025)
| % Change Since: -14.50%|
Next Earnings Date:Dec 11, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in revenue growth, operational efficiencies, and strategic focus on the LineaRx subsidiary. However, it also outlined challenges such as an increased net loss, a major business segment exit, and ongoing concerns about the company's financial stability. Despite these challenges, the strategic restructuring and new opportunities in the LineaRx segment suggest a cautiously optimistic outlook.Q1-2025 Updates
Positive Updates
Revenue Growth
Total revenues for the first quarter of fiscal 2025 were $1.2 million, a 34.7% increase compared with $891,000 for the same period of fiscal 2024, driven by higher product revenue.
Operational Efficiency
Operating loss improved to $3 million from $3.8 million in the prior year period due to lower selling, general, and administrative costs.
LineaRx Expansion
LineaRx's customer acquisition rates exceeded expectations with over twenty-five customer projects engaged in fiscal 2024, anticipating multiple projects to enter the clinic in calendar 2025.
GMP Site Certification
Certification of the GMP Site One facility achieved, showcasing a low CapEx approach to enzymatic DNA production at scale.
Strategic Restructuring
Implemented a strategic restructuring to bolster cash reserves and optimize cost structure, with a focus on LineaRx subsidiary.
Negative Updates
Net Loss Increase
Net loss for the first quarter was $2.7 million, an increase from $1.1 million in the prior year period.
Exit from DNA Tagging Business
Announced exit from the DNA tagging and security products and services business segment, resulting in a 20% workforce reduction and a one-time charge of approximately $300,000.
Going Concern Doubt
Disclosed substantial doubt of a going concern, dependent on the ability to implement business plans, generate revenues, and raise capital.
Company Guidance
During the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results call, the company announced several key financial and strategic updates. Total revenues for the first quarter increased to $1.2 million from $891,000 in the same period of fiscal 2024, primarily due to higher product revenue from the DNA tagging business segment and increased textiles isotopic testing services revenue. The company reported an operating loss of $3 million, an improvement from the $3.8 million loss in the prior year, primarily due to lower selling, general, and administrative costs. However, the net loss widened to $2.7 million compared to $1.1 million the previous year, with adjusted EBITDA improving to negative $2.9 million from negative $3.2 million. Cash and cash equivalents as of December 31 totaled $9.3 million, up from $6.4 million at the end of September 2024, reflecting proceeds from an October offering. As part of a strategic restructuring aimed at focusing on its LineaRx subsidiary, Applied DNA announced its exit from the DNA tagging and security products and services business segment and a 20% workforce reduction, with a one-time charge of approximately $300,000 anticipated. The company emphasized LineaRx's growth potential, highlighting its GMP Site One certification and the introduction of new products like Linea Donor DNA for CRISPR applications.Applied DNA Sciences Financial Statement Overview
Summary
Applied DNA Sciences is facing significant financial challenges with declining revenues and consistent net losses impacting profitability. The balance sheet is stable with low debt, but negative cash flows indicate operational inefficiencies. The company should focus on revenue growth and cost management to improve financial health.Income Statement
The company shows a declining revenue trend with significant losses. Revenue has decreased from $18.17 million in 2022 to $3.73 million TTM. Gross profit margin is low, and net profit margin is negative due to substantial net losses. These indicators suggest weak profitability and potential financial challenges.40
Negative
Balance Sheet
The balance sheet reveals a low debt-to-equity ratio, indicating minimal leverage and a stronger equity position. However, the equity ratio shows a decline from 58% in 2022 to 80% TTM, reflecting reduced asset base and increased equity. The return on equity is negative, which highlights profitability issues.50
Neutral
Cash Flow
Cash flows are under pressure with negative operating cash flow and free cash flow, indicating cash burn. Although financing cash flow is positive due to external funding, reliance on financing for operations is risky. Free cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash generation.35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.30M | 3.43M | 13.37M | 18.17M | 9.03M | 1.93M |
| Gross Profit | 1.30M | 1.02M | 5.53M | 5.05M | 4.93M | 1.21M |
| EBITDA | -13.18M | -13.33M | -9.59M | -12.68M | -11.68M | -12.25M |
| Net Income | -37.11M | -6.99M | -9.95M | -8.38M | -16.03M | -12.76M |
Balance Sheet | ||||||
| Total Assets | 9.93M | 12.79M | 13.65M | 22.27M | 14.42M | 11.34M |
| Cash, Cash Equivalents and Short-Term Investments | 4.73M | 6.43M | 7.15M | 15.22M | 6.55M | 7.79M |
| Total Debt | 334.40K | 739.16K | 1.24M | 0.00 | 0.00 | 2.35M |
| Total Liabilities | 2.95M | 3.82M | 8.78M | 9.36M | 3.30M | 5.63M |
| Stockholders Equity | 7.26M | 9.14M | 4.95M | 12.91M | 11.11M | 5.72M |
Cash Flow | ||||||
| Free Cash Flow | -13.26M | -14.12M | -6.30M | -9.47M | -15.94M | -12.21M |
| Operating Cash Flow | -12.58M | -13.71M | -6.22M | -8.98M | -13.39M | -11.14M |
| Investing Cash Flow | -663.37K | -407.90K | -1.10M | -489.55K | -2.55M | -1.06M |
| Financing Cash Flow | 7.54M | 13.40M | 0.00 | 18.13M | 14.70M | 19.43M |
Applied DNA Sciences Technical Analysis
Negative
3.48
Price Trends
4.66
Negative
8.33
Negative
63.47
Negative
Market Momentum
-0.45
Positive
32.55
Neutral
19.09
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APDN, the sentiment is Negative. The current price of 3.48 is below the 20-day moving average (MA) of 4.18, below the 50-day MA of 4.66, and below the 200-day MA of 63.47, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 32.55 is Neutral, neither overbought nor oversold. The STOCH value of 19.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APDN.
Applied DNA Sciences Risk Analysis
Applied DNA Sciences disclosed 41 risk factors in its most recent earnings report. Applied DNA Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Applied DNA Sciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $23.10M | ― | -14.76% | ― | 27.05% | 55.03% | |
51 Neutral | $7.88B | -0.12 | -39.83% | 2.18% | 21.38% | -1.56% | |
47 Neutral | $4.57M | ― | -303.74% | ― | -43.77% | 55.78% | |
46 Neutral | $13.29M | ― | -186.64% | ― | -1.90% | 87.72% | |
42 Neutral | $4.49M | ― | -130.75% | ― | -2.96% | 89.71% | |
34 Underperform | $3.30M | ― | -167.48% | ― | ― | 77.66% |
* Healthcare Sector Average
Performance Comparison
APDN
Applied DNA Sciences
3.48
-1,646.52
-99.79%
PRPO
Precipio
14.26
7.50
110.95%
NDRA
ENDRA Life Sciences
4.38
-18.14
-80.55%
INBS
Intelligent Bio Solutions
1.48
0.28
23.33%
ISPC
iSpecimen
0.82
-4.98
-85.86%
Applied DNA Sciences Corporate Events
Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Applied DNA Sciences Approves Reverse Stock Split
Neutral
Mar 12, 2025
On September 30, 2024, Applied DNA Sciences’ stockholders approved a reverse stock split to address non-compliance with Nasdaq’s minimum bid price requirements. Effective March 14, 2025, the 1-for-50 reverse stock split aims to reduce the number of outstanding shares from approximately 55.2 million to 1.1 million, helping the company regain compliance and maintain its Nasdaq listing.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.